Changes of Estimated Glomerular Filtration Rate and Glycated Hemoglobin A1c in DiabeticMacular Edema Patients Treated by Ranibizumab and Aflibercept in the Tertiary Referral Hospital

ASIA unversity > 醫學暨健康學院 > 視光學系 > 期刊論文 > Item 310904400/115336

jsp.display-item.identifier=請使用永久網址來引用或連結此文件: http://asiair.asia.edu.tw/ir/handle/310904400/115336

题名:	Changes of Estimated Glomerular Filtration Rate and Glycated Hemoglobin A1c in DiabeticMacular Edema Patients Treated by Ranibizumab and Aflibercept in the Tertiary Referral Hospital
作者:	Ku, Wei-Ning;Ku, Wei-Ning;Tie, Peng-Tai;Tien, Peng-Tai;林純如;Lin, Shun-Ju;Chi, Chun-Chi;Chiang, Chun-Chi;Hsia, Ning-Yi;Hsia, Ning-Yi;La, Chun-Ting;Lai, Chun-Ting;Mu, Chih-Hsin;Muo, Chih-Hsin;Bair, Henry;Bair, Henry;Huan-Sheng, C;Chen, Huan-Sheng;Li, Jane-Ming;Lin, Jane-Ming;蔡宜佑;Tsai, Yi-Yu
贡献者:	醫學暨健康學院視光學系
关键词:	DME;HbA1c;IVI;aflibercept;anti-VEGF;eGFR;intravitreal injections;ranibizumab.
日期:	2022-8-1
上传时间:	2023-03-29 01:30:56 (UTC+0)
出版者:	亞洲大學
摘要:	Background and Objectives: Intravitreal injections (IVI) of vascular endothelial growth factor (VEGF) inhibitors are guideline-indicated treatments for diabetic macular edema (DME). However, some recent data have suggested that IVI VEGF inhibitors might, through systemic absorption, lead to a reduction in renal function. Our study aims to compare changes in glycated hemoglobin A1c (HbA1c) and estimated glomerular filtration rate (eGFR) between patients who received IVI ranibizumab and aflibercept treatment and patients who have not received IVI treatments. Materials and Methods: There were 17,165 DME patients with documented ophthalmology visits in the China Medical University Hospital-Clinical Research Data Repository. Those with a history of ESRD or bevacizumab treatment history, and those with missing information on HbA1c or eGFR, were excluded. After matching by age (±2 years), gender, and the year of clinical visit, 154 patients with medical treatment (including ranibizumab and aflibercept) and 154 patients without medical treatment were included in the study. The difference between HbA1c and eGFR at baseline and 3 and 12 months after the index date between the two groups was assessed. Results: Mean HbA1c and eGFR decreased between baseline and 12 months after the index date in both groups (p < 0.05). Compared with the non-treatment group, the treatment group had significantly lower HbA1c 3 and 12 months after the index date. There was no significant difference in eGFR between the two groups. In the generalized estimating equations (GEE) model, HbA1c in the treatment group was lower than the non-treatment group (-0.44%, 95% CI = -0.75, -0.14), but eGFR was similar after adjusting for age, gender, and index-year. HbA1c and eGFR decreased with the time in the adjusted GEE model (p < 0.0001) in both groups. Conclusions: This study showed that eGFR decreased with age and time and was not related to IVI anti-VEGF treatments in our tertiary referral hospital. IVI anti-VEGF therapy was also associated with better HbA1c control. It is suggested that DME patients can receive intravitreal VEGF inhibitors without inducing more renal impairment.
显示于类别:	[視光學系] 期刊論文

文件中的档案:

档案	描述	大小	格式	浏览次数
index.html		0Kb	HTML	122	检视/开启

在ASIAIR中所有的数据项都受到原著作权保护.

数据加载中.....